RecruitingPhase 1NCT07342114

A Dose-Escalation Study of RO7875913 in Healthy Participants

A Phase I Dose-Escalation Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of RO7875913 in Healthy Volunteers

Sponsor

Genentech, Inc.

Enrollment

40 participants

Start Date

Mar 11, 2026

Study Type

INTERVENTIONAL

Conditions

Healthy Volunteers

Summary

The purpose of this study is to evaluate the safety, pharmacokinetics, and pharmacodynamics of RO7875913 in healthy participants.

Eligibility

Min Age: 18 YearsMax Age: 65 Years

Inclusion Criteria2

Agreement to adhere to the contraception requirements
Body weight > 40 kilogram (kg) with a body mass index of 18-30 kg per meter square (kg/m\^2)

Exclusion Criteria8

Positive test result for hepatitis B surface antigen, hepatitis C virus (HCV), or human immunodeficiency virus (HIV) antibody screen
History of any malignancy
Major surgical procedure within 28 days prior to initiation of study treatment, or anticipation of need for a major surgical procedure during the study
History or clinical manifestations of significant metabolic, hepatic, renal, pulmonary, cardiovascular, hematologic, gastrointestinal, urologic, neurologic, or psychiatric disorders
Known allergy or hypersensitivity to any component of the RO7875913 formulation
Treatment with investigational biologic therapy (or blinded comparator) within 90 days or 5 drug elimination half-lives, whichever is longer, prior to initiation of study drug
Treatment with investigational non-biologic therapy (or blinded comparator) within 28 days or 5 drug elimination half-lives, whichever is longer, prior to initiation of study drug
Treatment with any immunosuppressive medication within 28 days or 5 drug elimination half-lives, whichever is longer, prior to initiation of study drug

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGRO7875913

Participants will receive RO7875913 as per the schedule described in the protocol.

DRUGPlacebo

Participants will receive placebo as per the schedule described in the protocol.

Locations(1)

New Zealand Clinical Research - Christchurch

Christchurch, Canterbury, New Zealand

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07342114

Related Trials

Cytapheresis of Volunteer Donors

NCT001043251 location

Collection of Tissue Specimens From Patients With Solid Tumors or Blood Disorders and Their HLA-Compatible Family Members

NCT000710451 location